Related Experiment Video

Updated: Mar 23, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K

A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer

Hephzibah Rani S Tagaram1, Dhimant Desai2, Guangfu Li3

  • 1Department of Surgery, Pennsylvania State University, Hershey, PA 17033, USA. htagaram@gmail.com.

Pharmaceuticals (Basel, Switzerland)
|March 30, 2016
PubMed

Insights

The novel compound PBISe demonstrates significant anti-cancer effects against hepatocellular carcinoma (HCC). It effectively inhibits tumor growth and promotes apoptosis by targeting key signaling pathways, offering a promising new therapeutic strategy for HCC.

Area of Science:

  • Oncology
  • Biochemistry
  • Pharmacology

Background:

  • Hepatocellular carcinoma (HCC) is a leading cause of cancer death with limited treatment options.
  • Aberrant activation of Erk, Akt, and STAT3 signaling pathways contributes to HCC progression.
  • There is an urgent need for novel therapeutic strategies to combat HCC.

Purpose of the Study:

  • To investigate the anti-proliferative and pro-apoptotic potential of Se,Se'-1,4-phenylenebis(1,2-ethanediyl) bisisoselenourea (PBISe) in HCC.
  • To elucidate the mechanisms underlying PBISe's effects on HCC cell lines and a murine HCC model.
  • To evaluate PBISe as a potential chemotherapeutic agent for HCC treatment.

Main Methods:

  • In vitro studies using four human HCC cell lines assessed cell viability and apoptosis (caspase 3/7, PARP cleavage, annexin-V, TUNEL assays).
  • In vivo studies utilized a spontaneous murine HCC model, monitoring tumor size via MRI.
  • Western blotting analyzed the impact of PBISe on PI3K, MAPK, and STAT3 signaling pathways; liver tissues were examined for proliferation and angiogenesis markers.

Main Results:

  • PBISe significantly induced apoptosis in HCC cells, evidenced by increased caspase-3/7 activity and PARP cleavage.
  • In vivo, PBISe treatment led to a significant reduction in tumor size (p < 0.007).
  • PBISe inhibited key signaling pathways (PI3K, MAPK, STAT3) and reduced markers of proliferation (PCNA) and angiogenesis (Vegf-A, Vegf-R3, CD34).

Conclusions:

  • PBISe exhibits potent chemotherapeutic effects against hepatocellular carcinoma.
  • The compound effectively inhibits HCC tumor growth and induces apoptosis through modulation of critical signaling pathways.
  • PBISe represents a promising therapeutic candidate for HCC treatment.
Keywords:
apoptotic and angiogenesis markershepatocellular cancerinhibitionselenium

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.4K
Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula09:03

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Published on: January 26, 2024

778

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K